GlassScriptPhysician profile
Amrit P Narula
NPI 1720050222
$9,894.01
in general payments reported to CMS, 2019-2025
33 companies · $2,210 in 2025
The $2,210 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $542 · 2021: $798 · 2022: $1,405 · 2023: $1,789 · 2024: $2,485 · 2025: $2,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,484.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,177.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,565.35 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,078.11 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $705.76 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $526.46 | 2022-2025 | Dupixent |
| Genzyme Corporation | $502.38 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $479.96 | 2019-2025 | Rebyota, Clenpiq |
| Ardelyx, INC. | $402.56 | 2022-2025 | Ibsrela |
| Celgene Corporation | $394.53 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $273.08 | 2024-2025 | Zenpep |
| Pfizer INC. | $267.75 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $254.56 | 2022-2024 | Linzess |
| Braintree Laboratories, INC. | $206.03 | 2019-2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $190.16 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $119.63 | 2020-2023 | Dificid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $90.60 | 2021-2023 | Ocaliva |
| Madrigal Pharmaceuticals | $76.17 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $76.17 | 2025 | Iqirvo |
| Shionogi INC | $67.40 | 2019 | |
| Gilead Sciences, INC. | $64.85 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $53.62 | 2022-2023 | |
| Steris Corporation | $52.53 | 2020 | |
| Celltrion USA INC. | $47.70 | 2025 | Vegzelma |
| Ucb, INC. | $44.07 | 2019 | |
| Echosens North America, INC. | $34.54 | 2019 | |
| Amgen INC. | $26.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2024 | Cyltezo |
| Astrazeneca Pharmaceuticals LP | $19.91 | 2025 | Airsupra |
| Capsovision, INC. | $17.95 | 2025 | Capsocam Plus |
| Axonics, INC. | $17.92 | 2023 | Axonics |
| Medtronic, INC. | $16.19 | 2021 | |
| Novo Nordisk INC | $11.93 | 2019 | |
| Dova Pharmaceuticals | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrit Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.